文献速递血液净化与透析

CYCLE-HD随机对照试验的成本效果分析

A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial.
PubMed 文献 · Kidney Int Rep · 2021-04-08

该研究对CYCLE-HD试验中接受中心维持性血液透析的成人终末期肾病患者进行回顾性正式成本效果分析,评估6个月每周三次透析中骑行项目的医疗费用影响。基于109名参与者的分析显示,干预组医疗利用成本降低,在每获得一个QALY支付意愿为2万和3万英镑时,IDC具有成本效果的概率分别为73%(试验内6个月)和93%–94%( extrapolate至12个月)。结论认为6个月IDC项目具有成本效果,应优先在全国推广。

要点

  • 6个月透析中骑行可降低医疗利用成本,在2万–3万英镑/QALY阈值下具成本效果。
  • 试验内6个月成本效果概率为73%, extrapolate至12个月升至93%–94%。
  • 敏感性分析广泛支持主要 findings,支持全国推广该项目。

核心结论

  • 6个月透析中骑行项目具有成本效果,应优先在全国推广。

研究设计与样本

  • 回顾性正式成本效果分析,纳入CYCLE-HD试验中接受中心维持性血液透析的成人终末期肾病患者。
  • 从医疗服务视角分析,纳入实施IDC干预的成本,基础分析包括6个月试验内和12个月试验内及试验后分析。
  • 基础分析基于109名参与者(对照组56例,IDC组53例)。

主要发现

  • 试验内6个月分析显示IDC组医疗利用成本降低,在每QALY支付意愿2万和3万英镑时成本效果概率为73%。
  • QoL数据 extrapolate至12个月时,在每QALY支付意愿2万和3万英镑时成本效果概率分别为93%和94%。
  • 敏感性分析广泛证实上述 findings。

临床怎么用

  • 可考虑将6个月每周三次透析中骑行项目纳入常规透析照护以降低医疗成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: No formal cost-effectiveness analysis has been performed for programs of cycling exercise during dialysis (intradialytic cycling [IDC]). The objective of this analysis is to determine the effect of a 6-month program of IDC on health care costs. METHODS: This is a retrospective formal cost-effectiveness analysis of adult participants with end-stage kidney disease undertaking in-center maintenance hemodialysis enrolled in the CYCLE-HD trial. Data on hospital utilization, primary care consultations, and prescribed medications were extracted from medical records for the 6 months before, during, and after a 6-month program of thrice-weekly IDC. The cost-effectiveness analysis was conducted from a health care service perspective and included the cost of implementing the IDC intervention. The base-case analyses included a 6-month "within trial" analysis and a 12-month "within and posttrial" analysis considering health care utilization and quality of life (QoL) outcomes. RESULTS: Data from the base-case within trial analysis, based on 109 participants (n = 56 control subjects and n = 53 IDC subjects) showed a reduction in health care utilization costs between groups, favoring the IDC group, and a 73% chance of IDC being cost-effective compared with control subjects at a willingness to pay of £20,000 and £30,000 per quality-adjusted life year (QALY) gained. When QoL data points were extrapolated forward to 12 months, the probability of IDC being cost-effective was 93% and 94% at £20,000 and £30,000 per QALY gained. Sensitivity analysis broadly confirms these findings. CONCLUSION: A 6-month program of IDC is cost-effective and the implementation of these programs nationally should be a priority.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. March DS, Hurt AW, Grantham CE, et al. A Cost-Effective Analysis of the CYCLE-HD Randomized Controlled Trial. Kidney Int Rep. 2021. PMID: 34169195. doi:10.1016/j.ekir.2021.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。